Lv4
532 积分 2023-04-11 加入
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
3天前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
3天前
已完结
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
5天前
已完结
New exploration of KRASG12D inhibitors and the mechanisms of resistance
5天前
已完结
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
5天前
已完结
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma
5天前
已完结
B7 homolog 3 in pancreatic cancer
5天前
已完结
Comprehensive molecular profiling of lung adenocarcinoma
5天前
已完结
Drugging the undruggable RAS: Mission Possible?
5天前
已完结
A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors
5天前
已完结
皖公网安备34019202002308
